CD274 and neoplasm: Over the recent years, several different biomarkers have been evaluated in order to replace or complement PD-L1 predictivity, e.g. neoantigens, tumor-infiltrating immune cells and tumor mutational burden (TMB), however none have proven good enough to tailor therapy.